ID

41168

Descripción

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.; ODM derived from: https://clinicaltrials.gov/show/NCT01750281

Link

https://clinicaltrials.gov/show/NCT01750281

Palabras clave

Versiones (1)
  1. 4/7/20 4/7/20 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

4 de julio de 2020

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01750281

Inglés

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01750281

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
provision of signed, written and dated informed consent prior to any study specific procedures
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
male or female, aged 18 years or older
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
histological or cytological confirmation of locally advanced or metastatic nsclc (iiib-iv)
Descripción

Locally Advanced Lung Non-Small Cell Carcinoma TNM clinical staging | Metastatic non-small cell lung cancer TNM clinical staging

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C5205550
UMLS CUI [1,2]
C3258246
UMLS CUI [2,1]
C0278987
UMLS CUI [2,2]
C3258246
prospective confirmation of kras mutation negative status as determined via an az approved laboratory
Descripción

KRAS Gene Mutation Negative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4684887
failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy
Descripción

Cancer treatment First line Failed | Advanced disease | Recurrent disease

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C1708063
UMLS CUI [1,3]
C0231175
UMLS CUI [2]
C0679246
UMLS CUI [3]
C0277556
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
mixed small cell and non-small cell lung cancer histology
Descripción

Small cell carcinoma of lung Non-Small Cell Lung Carcinoma Mixed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0149925
UMLS CUI [1,2]
C0007131
UMLS CUI [1,3]
C0205430
received >1 prior anti-cancer drug regimen for advanced or metastatic nsclc. patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
Descripción

Cancer treatment Quantity Advanced Lung Non-Small Cell Carcinoma | Cancer treatment Quantity Metastatic non-small cell lung cancer | Disease Progression During Maintenance therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C5206378
UMLS CUI [2,1]
C0920425
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0278987
UMLS CUI [3,1]
C0242656
UMLS CUI [3,2]
C0347984
UMLS CUI [3,3]
C0677908
other concomitant anti-cancer therapy agents except steroids
Descripción

Antineoplastic Agents Except Steroids

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003392
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C0038317
prior treatment with a mek (mitogen-activated protein kinase) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable)
Descripción

Prior Therapy | Mitogen-Activated Protein Kinase Inhibitor | docetaxel

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C1513344
UMLS CUI [3]
C0246415
the last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment.
Descripción

Therapeutic radiology procedure Recent | Palliative course of radiotherapy Recent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0475092
UMLS CUI [2,2]
C0332185
Volver a la parte superior de la página

Similar models

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01750281

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
provision of signed, written and dated informed consent prior to any study specific procedures
boolean
C0021430 (UMLS CUI [1])
Age
Item
male or female, aged 18 years or older
boolean
C0001779 (UMLS CUI [1])
Locally Advanced Lung Non-Small Cell Carcinoma TNM clinical staging | Metastatic non-small cell lung cancer TNM clinical staging
Item
histological or cytological confirmation of locally advanced or metastatic nsclc (iiib-iv)
boolean
C5205550 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0278987 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
KRAS Gene Mutation Negative
Item
prospective confirmation of kras mutation negative status as determined via an az approved laboratory
boolean
C4684887 (UMLS CUI [1])
Cancer treatment First line Failed | Advanced disease | Recurrent disease
Item
failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy
boolean
C0920425 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0679246 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Small cell carcinoma of lung Non-Small Cell Lung Carcinoma Mixed
Item
mixed small cell and non-small cell lung cancer histology
boolean
C0149925 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0205430 (UMLS CUI [1,3])
Cancer treatment Quantity Advanced Lung Non-Small Cell Carcinoma | Cancer treatment Quantity Metastatic non-small cell lung cancer | Disease Progression During Maintenance therapy
Item
received >1 prior anti-cancer drug regimen for advanced or metastatic nsclc. patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
boolean
C0920425 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C5206378 (UMLS CUI [1,3])
C0920425 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0278987 (UMLS CUI [2,3])
C0242656 (UMLS CUI [3,1])
C0347984 (UMLS CUI [3,2])
C0677908 (UMLS CUI [3,3])
Antineoplastic Agents Except Steroids
Item
other concomitant anti-cancer therapy agents except steroids
boolean
C0003392 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
Prior Therapy | Mitogen-Activated Protein Kinase Inhibitor | docetaxel
Item
prior treatment with a mek (mitogen-activated protein kinase) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable)
boolean
C1514463 (UMLS CUI [1])
C1513344 (UMLS CUI [2])
C0246415 (UMLS CUI [3])
Therapeutic radiology procedure Recent | Palliative course of radiotherapy Recent
Item
the last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment.
boolean
C1522449 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0475092 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial